Floatz logo

FDOPA

Recurrent Childhood Gliomatosis Cerebri

Erik MittraSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Recurrent Childhood Gliomatosis Cerebri cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Göttingen
Phase 3BB
Inno-206
Meyer Children's Hospital IRCCS
Phase 2CCC
DEXAMETHASONE
Pediatric Brain Tumor Consortium
Phase 1CC
HSV-1716
Pediatric Brain Tumor Consortium
Phase 1CC
ONC 206
Jazz Pharmaceuticals
Phase 1CC
Palbociclib
Pediatric Brain Tumor Consortium
Phase 1CC
Gefetinib
National Cancer Institute (NCI)
Phase 1/2NR

Same molecule, other indications

FDOPA is also rated in:

congenital isolated hyperinsulinismDormant
BB
Indicative ·
66 / 100
View asset →
brain gliomaDormant
B
Indicative ·
63 / 100
View asset →
Lewy body dementiaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →